FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / PLoS One / Blood type and breed-associated differences in cell marker e...
PloS one2019; 14(11); e0225161; doi: 10.1371/journal.pone.0225161

Blood type and breed-associated differences in cell marker expression on equine bone marrow-derived mesenchymal stem cells including major histocompatibility complex class II antigen expression.

Abstract: As the search for an immune privileged allogeneic donor mesenchymal stem cell (MSC) line continues in equine medicine, the characterization of the cells between different sources becomes important. Our research seeks to more clearly define the MSC marker expression of different equine MSC donors. The bone marrow-derived MSCs from two equine breeds and different blood donor-types were compared over successive culture passages to determine the differential expression of important antigens. Eighteen Thoroughbreds and 18 Standardbreds, including 8 blood donor (erythrocyte Aa, Ca, and Qa antigen negative) horses, were evaluated. Bone marrow was taken from each horse for isolation and culture of MSCs. Samples from passages 2, 4, 6, and 8 were labelled and evaluated by flow cytometry. The cell surface expression of CD11a/18, CD44, CD90 and MHC class II antigens were assessed. Trilineage assays for differentiation into adipogenic, chondrogenic and osteogenic lines were performed to verify characterization of the cells as MSCs. There were significant differences in mesenchymal stem cell marker expression between breeds and blood antigen-type groups over time. Standardbred horses showed a significantly lower expression of MHC class II than did Thoroughbred horses at passages 2, 4 and 6. CD90 was significantly higher in universal blood donor Standardbreds as compared to non-blood donor Standardbreds over all time points. All MSC samples showed high expression of CD44 and low expression of CD11a/18. Universal blood donor- type Standardbred MSCs from passages 2-4 show the most ideal antigen expression pattern of the horses and passages that we characterized for use as a single treatment of donor bone marrow-derived MSCs. Further work is needed to determine the significance of this differential expression along with the effect of the expression of MHC I on equine bone marrow-derived MSCs.
Get Full Text
Publication Date: 2019-11-20 PubMed ID: 31747418PubMed Central: PMC6867698DOI: 10.1371/journal.pone.0225161Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research investigates the differences in cell marker expression of mesenchymal stem cells (MSC) derived from the bone marrow of two different horse breeds and different blood type donors, focusing on their expression of major histocompatibility complex (MHC) class II antigens. The study found breed and blood type-associated differences in cell marker expression over time, specifically highlighting universal blood donor type Standardbred horse’s MSCs as ideal for use as donor cells for single treatment bone marrow-derived MSCs.

Introduction

  • The study is a part of ongoing research in equine medicine to identify an immune privileged allogeneic donor for mesenchymal stem cells (MSCs).
  • Researchers are interested in understanding cell marker expression by different equine MSC donors, as these markers can heavily influence the effectiveness and compatibility of the resulting treatments.

Methodology

  • The bone marrow from two different horse breeds (18 Thoroughbreds and 18 Standardbreds), including 8 blood donor horses negative for erythrocyte antigens Aa, Ca, and Qa, was collected for this study.
  • The bone marrow was cultured to produce MSCs which were then evaluated at specific culture passages (2, 4, 6, and 8) using flow cytometry.
  • Assessment of cell surface expression of CD11a/18, CD44, CD90, and MHC class II antigens was done.
  • Trilineage assays were also performed to verify the characterization of cultured cells as MSCs through their capacity to differentiate into adipogenic, chondrogenic, and osteogenic lines.

Results

  • There were notable differences in MSC marker expression over time between Standardbred and Thoroughbred horses and among different blood antigen-type groups.
  • The researchers found that MSCs from Standardbred horses showed significantly lower MHC class II expression than those from Thoroughbred horses at passages 2, 4, and 6.
  • CD90 expression was significantly higher in MSCs from universal blood donor Standardbreds compared to non-blood donor Standardbreds across all time points.
  • All MSC samples exhibited high CD44 expression and low CD11a/18 expression.

Conclusions and Further Research

  • The findings indicate that the MSCs from universal blood donor type Standardbred horses, particularly from passages 2-4, showed the most ideal antigen expression pattern for use as donor bone marrow-derived MSCs.
  • However, more research is needed to understand the biological and clinical implications of these differences in cell marker expressions, especially the effect of MHC I expression on equine bone marrow-derived MSCs.

Cite This Article

APA
Kamm JL, Parlane NA, Riley CB, Gee EK, Dittmer KE, McIlwraith CW. (2019). Blood type and breed-associated differences in cell marker expression on equine bone marrow-derived mesenchymal stem cells including major histocompatibility complex class II antigen expression. PLoS One, 14(11), e0225161. https://doi.org/10.1371/journal.pone.0225161

Publication

PloS one
ISSN: 1932-6203
NlmUniqueID: 101285081
Country: United States
Language: English
Volume: 14
Issue: 11
Pages: e0225161
PII: e0225161

Researcher Affiliations

Kamm, J Lacy
  • Massey University, School of Veterinary Science, Massey University, Palmerston North, New Zealand.
  • Veterinary Associates, Karaka, Auckland, New Zealand.
Parlane, Natalie A
  • AgResearch, Hopkirk Research Institute, Massey University, Palmerston North, New Zealand.
Riley, Christopher B
  • Massey University, School of Veterinary Science, Massey University, Palmerston North, New Zealand.
Gee, Erica K
  • Massey University, School of Veterinary Science, Massey University, Palmerston North, New Zealand.
Dittmer, Keren E
  • Massey University, School of Veterinary Science, Massey University, Palmerston North, New Zealand.
McIlwraith, C Wayne
  • Massey University, School of Veterinary Science, Massey University, Palmerston North, New Zealand.
  • Colorado State University, Orthopaedic Research Center, Fort Collins, Colorado, United States of America.

MeSH Terms

  • Animals
  • Biomarkers / blood
  • Bone Marrow Cells / metabolism
  • Cells, Cultured
  • Histocompatibility Antigens / genetics
  • Histocompatibility Antigens / metabolism
  • Horses / blood
  • Horses / genetics
  • Hyaluronan Receptors / genetics
  • Hyaluronan Receptors / metabolism
  • Mesenchymal Stem Cells / metabolism
  • Thy-1 Antigens / genetics
  • Thy-1 Antigens / metabolism
  • Veterinary Medicine / methods

Conflict of Interest Statement

I have read the journal's policy and the authors of this manuscript have the following competing interests: C. Wayne McIlwraith and Lacy Kamm are directors and owners of Advanced Regenerative Therapies, New Zealand. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

References

This article includes 50 references
  1. Richardson SM, Kalamegam G, Pushparaj PN, Matta C, Memic A, Khademhosseini A, Mobasheri R, Poletti FL, Hoyland JA, Mobasheri A. Mesenchymal stem cells in regenerative medicine: Focus on articular cartilage and intervertebral disc regeneration.. Methods 2016 Apr 15;99:69-80.
    pubmed: 26384579doi: 10.1016/j.ymeth.2015.09.015google scholar: lookup
  2. Joswig AJ, Mitchell A, Cummings KJ, Levine GJ, Gregory CA, Smith R 3rd, Watts AE. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model.. Stem Cell Res Ther 2017 Feb 28;8(1):42.
    pmc: PMC5329965pubmed: 28241885doi: 10.1186/s13287-017-0503-8google scholar: lookup
  3. McIlwraith CW, Frisbie DD, Rodkey WG, Kisiday JD, Werpy NM, Kawcak CE, Steadman JR. Evaluation of intra-articular mesenchymal stem cells to augment healing of microfractured chondral defects.. Arthroscopy 2011 Nov;27(11):1552-61.
    pubmed: 21862278doi: 10.1016/j.arthro.2011.06.002google scholar: lookup
  4. Godwin EE, Young NJ, Dudhia J, Beamish IC, Smith RK. Implantation of bone marrow-derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficial digital flexor tendon.. Equine Vet J 2012 Jan;44(1):25-32.
    doi: 10.1111/j.2042-3306.2011.00363.xpubmed: 21615465google scholar: lookup
  5. Ferris DJ, Frisbie DD, Kisiday JD, McIlwraith CW, Hague BA, Major MD, Schneider RK, Zubrod CJ, Kawcak CE, Goodrich LR. Clinical outcome after intra-articular administration of bone marrow derived mesenchymal stem cells in 33 horses with stifle injury.. Vet Surg 2014 Mar;43(3):255-65.
    doi: 10.1111/j.1532-950X.2014.12100.xpubmed: 24433318google scholar: lookup
  6. Garvican ER, Cree S, Bull L, Smith RK, Dudhia J. Viability of equine mesenchymal stem cells during transport and implantation.. Stem Cell Res Ther 2014 Aug 8;5(4):94.
    pmc: PMC4247703pubmed: 25107289doi: 10.1186/scrt483google scholar: lookup
  7. Colbath AC, Dow SW, Phillips JN, McIlwraith CW, Goodrich LR. Autologous and Allogeneic Equine Mesenchymal Stem Cells Exhibit Equivalent Immunomodulatory Properties In Vitro.. Stem Cells Dev 2017 Apr 1;26(7):503-511.
    doi: 10.1089/scd.2016.0266pubmed: 27958776google scholar: lookup
  8. Pezzanite LM, Fortier LA, Antczak DF, Cassano JM, Brosnahan MM, Miller D, Schnabel LV. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.. Stem Cell Res Ther 2015 Apr 12;6(1):54.
    pmc: PMC4414005pubmed: 25889095doi: 10.1186/s13287-015-0053-xgoogle scholar: lookup
  9. Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJ, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.. Stem Cell Res Ther 2014 Jan 24;5(1):13.
    pmc: PMC4055004pubmed: 24461709doi: 10.1186/scrt402google scholar: lookup
  10. Portalska KJ, Groen N, Krenning G, Georgi N, Mentink A, Harmsen MC, van Blitterswijk C, de Boer J. The effect of donor variation and senescence on endothelial differentiation of human mesenchymal stromal cells.. Tissue Eng Part A 2013 Nov;19(21-22):2318-29.
    doi: 10.1089/ten.TEA.2012.0646pubmed: 23676150google scholar: lookup
  11. Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?. Immunol Cell Biol 2013 Jan;91(1):40-51.
    doi: 10.1038/icb.2012.67pubmed: 23207278google scholar: lookup
  12. Berglund AK, Fortier LA, Antczak DF, Schnabel LV. Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells.. Stem Cell Res Ther 2017 Dec 22;8(1):288.
    pmc: PMC5741939pubmed: 29273086doi: 10.1186/s13287-017-0742-8google scholar: lookup
  13. Consentius C, Reinke P, Volk HD. Immunogenicity of allogeneic mesenchymal stromal cells: what has been seen in vitro and in vivo?. Regen Med 2015;10(3):305-15.
    doi: 10.2217/rme.15.14pubmed: 25933239google scholar: lookup
  14. Zangi L, Margalit R, Reich-Zeliger S, Bachar-Lustig E, Beilhack A, Negrin R, Reisner Y. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells.. Stem Cells 2009 Nov;27(11):2865-74.
    pubmed: 19750539doi: 10.1002/stem.217google scholar: lookup
  15. Benichou G, Yamada Y, Yun SH, Lin C, Fray M, Tocco G. Immune recognition and rejection of allogeneic skin grafts.. Immunotherapy 2011 Jun;3(6):757-70.
    doi: 10.2217/imt.11.2pmc: PMC3738014pubmed: 21668313google scholar: lookup
  16. Barrachina L, Remacha AR, Romero A, Vázquez FJ, Albareda J, Prades M, Ranera B, Zaragoza P, Martín-Burriel I, Rodellar C. Effect of inflammatory environment on equine bone marrow derived mesenchymal stem cells immunogenicity and immunomodulatory properties.. Vet Immunol Immunopathol 2016 Mar;171:57-65.
    doi: 10.1016/j.vetimm.2016.02.007pubmed: 26964718google scholar: lookup
  17. Alonso Arias R, López-Vázquez A, López-Larrea C. Immunology and the challenge of transplantation.. Adv Exp Med Biol 2012;741:27-43.
    doi: 10.1007/978-1-4614-2098-9_3pubmed: 22457101google scholar: lookup
  18. Huang XP, Ludke A, Dhingra S, Guo J, Sun Z, Zhang L, Weisel RD, Li RK. Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart.. FASEB J 2016 Sep;30(9):3069-82.
    pubmed: 27221978doi: 10.1096/fj.201600331rgoogle scholar: lookup
  19. Mei L, Shen B, Ling P, Liu S, Xue J, Liu F, Shao H, Chen J, Ma A, Liu X. Culture-expanded allogenic adipose tissue-derived stem cells attenuate cartilage degeneration in an experimental rat osteoarthritis model.. PLoS One 2017;12(4):e0176107.
    doi: 10.1371/journal.pone.0176107pmc: PMC5395232pubmed: 28419155google scholar: lookup
  20. Paebst F, Piehler D, Brehm W, Heller S, Schroeck C, Tárnok A, Burk J. Comparative immunophenotyping of equine multipotent mesenchymal stromal cells: an approach toward a standardized definition.. Cytometry A 2014 Aug;85(8):678-87.
    pubmed: 24894974doi: 10.1002/cyto.a.22491google scholar: lookup
  21. De Schauwer C, Piepers S, Van de Walle GR, Demeyere K, Hoogewijs MK, Govaere JL, Braeckmans K, Van Soom A, Meyer E. In search for cross-reactivity to immunophenotype equine mesenchymal stromal cells by multicolor flow cytometry.. Cytometry A 2012 Apr;81(4):312-23.
    pubmed: 22411893doi: 10.1002/cyto.a.22026google scholar: lookup
  22. Zahedi M, Parham A, Dehghani H, Mehrjerdi HK. Stemness Signature of Equine Marrow-derived Mesenchymal Stem Cells.. Int J Stem Cells 2017 May 30;10(1):93-102.
    doi: 10.15283/ijsc16036pmc: PMC5488781pubmed: 28222255google scholar: lookup
  23. Radcliffe CH, Flaminio MJ, Fortier LA. Temporal analysis of equine bone marrow aspirate during establishment of putative mesenchymal progenitor cell populations.. Stem Cells Dev 2010 Feb;19(2):269-82.
    doi: 10.1089/scd.2009.0091pmc: PMC3138180pubmed: 19604071google scholar: lookup
  24. Song X, Hong C, Zheng Q, Zhao H, Song K, Liu Z, Shen J, Li Y, Wang J, Shen T. Differentiation potential of rabbit CD90-positive cells sorted from adipose-derived stem cells in vitro.. In Vitro Cell Dev Biol Anim 2017 Jan;53(1):77-82.
    pubmed: 27553254doi: 10.1007/s11626-016-0081-6google scholar: lookup
  25. Zhao YF, Xiong W, Wu XL. Mesenchymal stem cell-based developmental endothelial locus-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice.. Mol Med Rep 2014 May;9(5):1583-9.
    doi: 10.3892/mmr.2014.1988pubmed: 24573341google scholar: lookup
  26. Dvorakova J, Hruba A, Velebny V, Kubala L. Isolation and characterization of mesenchymal stem cell population entrapped in bone marrow collection sets.. Cell Biol Int 2008 Sep;32(9):1116-25.
    doi: 10.1016/j.cellbi.2008.04.024pubmed: 18562221google scholar: lookup
  27. Becht JL, Semrad SD. Hematology, blood typing, and immunology of the neonatal foal.. Vet Clin North Am Equine Pract 1985 Apr;1(1):91-116.
    doi: 10.1016/s0749-0739(17)30771-xpubmed: 3907769google scholar: lookup
  28. Angelos J, Oppenheim Y, Rebhun W, Mohammed H, Antczak DF. Evaluation of breed as a risk factor for sarcoid and uveitis in horses.. Anim Genet 1988;19(4):417-25.
    doi: 10.1111/j.1365-2052.1988.tb00833.xpubmed: 3232865google scholar: lookup
  29. Tomlinson JE, Taberner E, Boston RC, Owens SD, Nolen-Walston RD. Survival Time of Cross-Match Incompatible Red Blood Cells in Adult Horses.. J Vet Intern Med 2015 Nov-Dec;29(6):1683-8.
    doi: 10.1111/jvim.13627pmc: PMC4895677pubmed: 26478135google scholar: lookup
  30. Ogawa M, Larue AC, Watson PM, Watson DK. Hematopoietic stem cell origin of mesenchymal cells: opportunity for novel therapeutic approaches.. Int J Hematol 2010 Apr;91(3):353-9.
    doi: 10.1007/s12185-010-0554-4pubmed: 20336396google scholar: lookup
  31. Waselau M, Sutter WW, Genovese RL, Bertone AL. Intralesional injection of platelet-rich plasma followed by controlled exercise for treatment of midbody suspensory ligament desmitis in Standardbred racehorses.. J Am Vet Med Assoc 2008 May 15;232(10):1515-20.
    doi: 10.2460/javma.232.10.1515pubmed: 18479242google scholar: lookup
  32. Lacitignola L, Crovace A, Rossi G, Francioso E. Cell therapy for tendinitis, experimental and clinical report.. Vet Res Commun 2008 Sep;32 Suppl 1:S33-8.
    pubmed: 18686004doi: 10.1007/s11259-008-9085-3google scholar: lookup
  33. Kisiday JD, Kopesky PW, Evans CH, Grodzinsky AJ, McIlwraith CW, Frisbie DD. Evaluation of adult equine bone marrow- and adipose-derived progenitor cell chondrogenesis in hydrogel cultures.. J Orthop Res 2008 Mar;26(3):322-31.
    pubmed: 17960654doi: 10.1002/jor.20508google scholar: lookup
  34. Gibco. StemPro Differentiation Kit: Product use manual. Waltham, MA, USA2014.
  35. Snyder L. Blood Typing. Clinical Veterinary Advisor: The Horse Pennsylvania, USA: Elsevier Saunders; 2012.
  36. Hardy J. Venous and arterial catheterization and fluid therapy. Equine Anesthesia: Monitoring and Emergency Therapy 2nd ed. Missouri, USA: Mosby Elsevier; 2009.
  37. Whittington NC, Wray S. Suppression of Red Blood Cell Autofluorescence for Immunocytochemistry on Fixed Embryonic Mouse Tissue.. Curr Protoc Neurosci 2017 Oct 23;81:2.28.1-2.28.12.
    pmc: PMC5657453pubmed: 29058770doi: 10.1002/cpns.35google scholar: lookup
  38. Maecker HT, Frey T, Nomura LE, Trotter J. Selecting fluorochrome conjugates for maximum sensitivity.. Cytometry A 2004 Dec;62(2):169-73.
    pubmed: 15536642doi: 10.1002/cyto.a.20092google scholar: lookup
  39. Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B. Aging of mesenchymal stem cell in vitro.. BMC Cell Biol 2006 Mar 10;7:14.
    doi: 10.1186/1471-2121-7-14pmc: PMC1435883pubmed: 16529651google scholar: lookup
  40. Cribari-Neto F, ZA. Beta Regression in R. Journal of Statistical Software 2010;34(2):1–24.
  41. He X, Houde ALS, Pitcher TE, Heath DD. Genetic architecture of gene transcription in two Atlantic salmon (Salmo salar) populations.. Heredity (Edinb) 2017 Aug;119(2):117-124.
    doi: 10.1038/hdy.2017.24pmc: PMC5520547pubmed: 28467401google scholar: lookup
  42. Talbot B, Chen TW, Zimmerman S, Joost S, Eckert AJ, Crow TM, Semizer-Cuming D, Seshadri C, Manel S. Combining Genotype, Phenotype, and Environment to Infer Potential Candidate Genes.. J Hered 2017 Mar 1;108(2):207-216.
    doi: 10.1093/jhered/esw077pubmed: 28003371google scholar: lookup
  43. Kundrotas G, Gasperskaja E, Slapsyte G, Gudleviciene Z, Krasko J, Stumbryte A, Liudkeviciene R. Identity, proliferation capacity, genomic stability and novel senescence markers of mesenchymal stem cells isolated from low volume of human bone marrow.. Oncotarget 2016 Mar 8;7(10):10788-802.
    doi: 10.18632/oncotarget.7456pmc: PMC4905439pubmed: 26910916google scholar: lookup
  44. Esteves CL, Sheldrake TA, Dawson L, Menghini T, Rink BE, Amilon K, Khan N, Péault B, Donadeu FX. Equine Mesenchymal Stromal Cells Retain a Pericyte-Like Phenotype.. Stem Cells Dev 2017 Jul 1;26(13):964-972.
    doi: 10.1089/scd.2017.0017pmc: PMC5510672pubmed: 28376684google scholar: lookup
  45. Ranera B, Lyahyai J, Romero A, Vázquez FJ, Remacha AR, Bernal ML, Zaragoza P, Rodellar C, Martín-Burriel I. Immunophenotype and gene expression profiles of cell surface markers of mesenchymal stem cells derived from equine bone marrow and adipose tissue.. Vet Immunol Immunopathol 2011 Nov 15;144(1-2):147-54.
    doi: 10.1016/j.vetimm.2011.06.033pubmed: 21782255google scholar: lookup
  46. Campioni D, Lanza F, Moretti S, Ferrari L, Cuneo A. Loss of Thy-1 (CD90) antigen expression on mesenchymal stromal cells from hematologic malignancies is induced by in vitro angiogenic stimuli and is associated with peculiar functional and phenotypic characteristics.. Cytotherapy 2008;10(1):69-82.
    doi: 10.1080/14653240701762364pubmed: 18202976google scholar: lookup
  47. Moraes DA, Sibov TT, Pavon LF, Alvim PQ, Bonadio RS, Da Silva JR, Pic-Taylor A, Toledo OA, Marti LC, Azevedo RB, Oliveira DM. A reduction in CD90 (THY-1) expression results in increased differentiation of mesenchymal stromal cells.. Stem Cell Res Ther 2016 Jul 28;7(1):97.
    pmc: PMC4964048pubmed: 27465541doi: 10.1186/s13287-016-0359-3google scholar: lookup
  48. Favi PM, Benson RS, Neilsen NR, Hammonds RL, Bates CC, Stephens CP, Dhar MS. Cell proliferation, viability, and in vitro differentiation of equine mesenchymal stem cells seeded on bacterial cellulose hydrogel scaffolds.. Mater Sci Eng C Mater Biol Appl 2013 May 1;33(4):1935-44.
    pubmed: 23498215doi: 10.1016/j.msec.2012.12.100google scholar: lookup
  49. van Kooyk Y, Weder P, Heije K, de Waal Malefijt R, Figdor CG. Role of intracellular Ca2+ levels in the regulation of CD11a/CD18 mediated cell adhesion.. Cell Adhes Commun 1993 May;1(1):21-32.
    doi: 10.3109/15419069309095679pubmed: 7915956google scholar: lookup
  50. Kisselbach L, Merges M, Bossie A, Boyd A. CD90 Expression on human primary cells and elimination of contaminating fibroblasts from cell cultures.. Cytotechnology 2009 Jan;59(1):31-44.
    doi: 10.1007/s10616-009-9190-3pmc: PMC2677147pubmed: 19296231google scholar: lookup

Citations

This article has been cited 14 times.
  1. Li S, Siengdee P, Oster M, Reyer H, Wimmers K, Ponsuksili S. Transcriptome changes during osteogenesis of porcine mesenchymal stem cells derived from different types of synovial membranes and genetic background. Sci Rep 2023 Jun 21;13(1):10048.
    doi: 10.1038/s41598-023-37260-4pubmed: 37344635google scholar: lookup
  2. Heilen LB, Roßgardt J, Dern-Wieloch J, Vogelsberg J, Staszyk C. Isolation and cultivation as well as in situ identification of MSCs from equine dental pulp and periodontal ligament. Front Vet Sci 2023;10:1116671.
    doi: 10.3389/fvets.2023.1116671pubmed: 36968463google scholar: lookup
  3. Cequier A, Vázquez FJ, Romero A, Vitoria A, Bernad E, García-Martínez M, Gascón I, Barrachina L, Rodellar C. The immunomodulation-immunogenicity balance of equine Mesenchymal Stem Cells (MSCs) is differentially affected by the immune cell response depending on inflammatory licensing and major histocompatibility complex (MHC) compatibility. Front Vet Sci 2022;9:957153.
    doi: 10.3389/fvets.2022.957153pubmed: 36337202google scholar: lookup
  4. Kamm JL, Riley CB, Parlane NA, Gee EK, McIlwraith CW. Immune response to allogeneic equine mesenchymal stromal cells. Stem Cell Res Ther 2021 Nov 12;12(1):570.
    doi: 10.1186/s13287-021-02624-ypubmed: 34772445google scholar: lookup
  5. Wright A, Arthaud-Day ML, Weiss ML. Therapeutic Use of Mesenchymal Stromal Cells: The Need for Inclusive Characterization Guidelines to Accommodate All Tissue Sources and Species. Front Cell Dev Biol 2021;9:632717.
    doi: 10.3389/fcell.2021.632717pubmed: 33665190google scholar: lookup
  6. Kamm JL, Riley CB, Parlane N, Gee EK, McIlwraith CW. Interactions Between Allogeneic Mesenchymal Stromal Cells and the Recipient Immune System: A Comparative Review With Relevance to Equine Outcomes. Front Vet Sci 2020;7:617647.
    doi: 10.3389/fvets.2020.617647pubmed: 33521090google scholar: lookup
  7. Kim M, Bae YK, Um S, Kwon JH, Kim GH, Choi SJ, Oh W, Jin HJ. A Small-Sized Population of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Shows High Stemness Properties and Therapeutic Benefit. Stem Cells Int 2020;2020:5924983.
    doi: 10.1155/2020/5924983pubmed: 32399043google scholar: lookup
  8. Capone A, Merlo B, Begni F, Iacono E. Equine Colostrum-Derived Mesenchymal Stromal Cells: A Potential Resource for Veterinary Regenerative Medicine. Vet Sci 2025 Jul 19;12(7).
    doi: 10.3390/vetsci12070681pubmed: 40711341google scholar: lookup
  9. Vachkova E, Arnhold S, Petrova V, Heimann M, Koynarski T, Simeonova G, Piperkov P. Transcriptional Factors Related to Cellular Kinetics, Apoptosis, and Tumorigenicity in Equine Adipose-Derived Mesenchymal Stem Cells (ASCs) Are Influenced by the Age of the Donors. Animals (Basel) 2025 Jun 28;15(13).
    doi: 10.3390/ani15131910pubmed: 40646808google scholar: lookup
  10. Heyman E, Olenic M, De Vlieghere E, De Smet S, Devriendt B, Thorrez L, De Schauwer C. Donor age and breed determine mesenchymal stromal cell characteristics. Stem Cell Res Ther 2025 Feb 28;16(1):99.
    doi: 10.1186/s13287-025-04236-2pubmed: 40022193google scholar: lookup
  11. Younesi FS, Hinz B. The Myofibroblast Fate of Therapeutic Mesenchymal Stromal Cells: Regeneration, Repair, or Despair?. Int J Mol Sci 2024 Aug 9;25(16).
    doi: 10.3390/ijms25168712pubmed: 39201399google scholar: lookup
  12. Yaneselli K, Ávila G, Rossi A, Rial A, Castro S, Estradé MJ, Suárez G, Algorta A. Impact of different formulations of platelet lysate on proliferative and immune profile of equine mesenchymal stromal cells. Front Vet Sci 2024;11:1410855.
    doi: 10.3389/fvets.2024.1410855pubmed: 39161460google scholar: lookup
  13. Moellerberndt J, Niebert S, Fey K, Hagen A, Burk J. Impact of platelet lysate on immunoregulatory characteristics of equine mesenchymal stromal cells. Front Vet Sci 2024;11:1385395.
    doi: 10.3389/fvets.2024.1385395pubmed: 38725585google scholar: lookup
  14. Purbantoro SD, Taephatthanasagon T, Purwaningrum M, Hirankanokchot T, Peralta S, Fiani N, Sawangmake C, Rattanapuchpong S. Trends of regenerative tissue engineering for oral and maxillofacial reconstruction in veterinary medicine. Front Vet Sci 2024;11:1325559.
    doi: 10.3389/fvets.2024.1325559pubmed: 38450027google scholar: lookup
Subscribe to our newsletter
Join 99,383 horse owners like you who receive our email updates on horse health and nutrition.